Welcome to our dedicated page for HealthLynked SEC filings (Ticker: HLYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HealthLynked's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HealthLynked's regulatory disclosures and financial reporting.
HealthLynked Corp. reported declining activity and continued losses for the quarter ended June 30, 2026. Total revenue was $249,830, down from $592,360 a year earlier, and the net loss to common shareholders was $819,705, versus $701,038 in the prior-year quarter. For the first six months of 2026, revenue was $673,295 and the net loss to common shareholders was $2,477,356.
The balance sheet shows a very strained position. Total assets were $1,592,990 against total liabilities of $9,346,257, resulting in a shareholders’ deficit of $7,753,267. Cash was only $12,844 and the working capital deficit was $7,351,419. The company relies heavily on debt, including SBA disaster loans and multiple high-cost notes with original issue discounts, default conversion features, and derivative liabilities of $23,663.
Management stated there is substantial doubt about the company’s ability to continue as a going concern without additional funding, citing ongoing losses and expected cash outflows over at least the next 12 months. In February 2026, prior obligations to the CEO were refinanced into a new $5,715,812 secured convertible note at 12% interest and a $4.25 conversion price, generating a $1,328,069 gain on extinguishment of debt but also significant ongoing fair value volatility.
HealthLynked Corp reported that Chief Financial Officer O'Leary George received a grant of 35,000 options to purchase common stock at an exercise price of $3.50 per share. These options vest in full upon successful approval for listing on the Nasdaq Capital Market while he serves as Interim CFO and expire on July 22, 2036. Following this award, he holds 37,612 derivative securities, including the new options and 2,612 warrants exercisable at $6.70 per share.
HealthLynked Corp. appointed director George O’Leary, 63, as part-time Interim Chief Financial Officer effective July 13, 2026, under a consulting engagement for three days per week at $15,000 per month. He also received 35,000 stock options with a $3.50 exercise price that vest only if the company receives approval for listing on the Nasdaq Capital Market while he is serving as interim CFO or during a 30-day notice period after termination.
On the same date, Jeremy Daniel ceased serving as Chief Financial Officer and moved into a corporate accounting role, with the company stating the transition did not result from any disagreement with management, the board, or its committees. Effective July 24, 2026, HealthLynked will eliminate the Chief Operating Officer position; incumbent COO Duncan McGillivray will leave that role and continue on an as-needed basis under an Independent Consulting Agreement as Senior Strategic Advisor.
HealthLynked Corp. is planning a $7,000,000 public offering of up to 1,750,000 shares of common stock, plus 150,000 shares registered for resale by a selling stockholder. The company expects an offering price between $4.00 and $6.00 per share and has applied to list on Nasdaq under the symbol HLYK; the deal will not close if listing is not approved.
At an assumed $5.00 price for 1,400,000 shares, net proceeds are estimated at about $6.16 million, or $7.14 million if the underwriter’s over-allotment is fully exercised. As of March 31, 2026, HealthLynked held cash of $23,973, with a working capital deficit of $6,658,253 and an accumulated deficit of $52,196,869, leading auditors to raise substantial doubt about its ability to continue as a going concern absent this financing and other capital raises.
HealthLynked Corp. reported weak first-quarter 2026 results, with total revenue of $423,465, down from $774,208 in the prior-year quarter. Patient service revenue and product revenue both decreased, while selling, general and administrative expenses rose to $847,281.
The company posted a net loss of $1,621,304 and a net loss to common shareholders of $1,657,651, or $0.57 per share, versus a $0.37 loss a year earlier. Cash was only $23,973 with a working capital deficit of $6,658,253 and shareholders’ deficit of $7,021,799. Management concluded there is substantial doubt about HealthLynked’s ability to continue as a going concern without additional funding.
HealthLynked Corp. is registering $7,000,000 of common stock in a public offering and 150,000 additional shares for resale by a selling stockholder. The primary sale is expected to price between $4.00 and $6.00 per share, with an assumed 1,400,000 shares at $5.00 for illustrative purposes.
The company estimates net proceeds of about $6.16 million (or $7.14 million with full over-allotment), to fund working capital, capital expenditures, research and development, sales and marketing, and repayment of specific debts. A significant portion of related-party convertible debt held by CEO Dr. Michael Dent is assumed to convert into equity for Nasdaq listing purposes.
HealthLynked reports cash of $37,136, a working capital deficit of $5.46 million and an accumulated deficit of $50.54 million as of December 31, 2025, leading to substantial doubt about its ability to continue as a going concern. Management believes proceeds from this offering, if completed, will help address liquidity concerns for at least the next twelve months.
HealthLynked Corp., a Nevada-based healthcare technology company, reports its annual results and outlines a shift from owning clinics toward a predominantly digital, technology-enabled model. The company operates three divisions: Digital Healthcare (its cloud-based HealthLynked Network with AI-assisted tools, telemedicine, concierge services, Oohvie, and a prescription discount program), Health Services (now a single functional medicine practice slated for divestiture), and Medical Distribution (MedOfficeDirect, an asset-light online medical supplies marketplace).
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing $37,136 in cash, a working capital deficit, significant accumulated losses, and the need for additional financing in the first half of 2026. The filing highlights heavy competition from large digital health, EMR, telemedicine, and big tech players, regulatory complexity across healthcare, privacy and billing laws, and reliance on Amazon Web Services. It also notes sizeable related-party convertible debt owed to CEO Dr. Michael Dent, which may create dilution and conflict-of-interest risks. To support payer-integration and value-based care pilots, HealthLynked entered an advisory arrangement with Palm Beach Accountable Care Organization in December 2025, though no revenue from such initiatives is assured.
HealthLynked Corp. is conducting a primary offering of up to 1,750,000 shares of common stock for $7,000,000 under an S-1 registration statement. The assumed price range is $4.00–$6.00 per share, with a base offering of 1,400,000 shares plus a 210,000-share over-allotment option.
The company’s stock currently trades on the OTCQB as “HLYK” and the offering is conditioned on approval for listing on Nasdaq; if Nasdaq does not approve the listing, the offering will not close. At a $5.00 midpoint, net proceeds are estimated at $6,160,000, to be used for working capital, capital expenditures, research and development, sales and marketing, and repayment of indebtedness.
As of September 30, 2025, HealthLynked had $10,911 in cash, a $5,201,336 working capital deficit and a $50,768,392 accumulated deficit, creating substantial doubt about its ability to continue as a going concern. The offering, together with the assumed conversion of $4,500,000 of related-party convertible debt into 1,058,824 shares at $4.25 per share, would turn a shareholders’ deficit of $(5,433,415) into pro forma equity of $5,226,585.
Common shares outstanding are expected to rise from 2,881,104 before the offering to 4,281,104 after the base deal, or 4,491,104 if the over-allotment is fully exercised, at the assumed price. New investors will experience immediate dilution; at a $5.00 price, pro forma net tangible book value would be $0.98 per share, implying dilution of $4.02 per share to new purchasers.
HealthLynked Corp. entered into a related-party financing by issuing a senior secured convertible promissory note with principal of $5,715,811.98 to the Mary S. Dent Gifting Trust, which is controlled by its CEO and Chairman, Dr. Michael Dent.
The new note consolidates prior obligations, including earlier promissory notes with principal of $4,338,191.70 and accrued interest of $737,180.26, undocumented advances of $339,840.02, and $300,600.00 of unpaid 2017 compensation. It carries 12% annual interest, rising to 18% upon uncured default, matures on February 2, 2029, and is secured by a first-priority lien on all company assets. The note is optionally convertible into common stock at $4.25 per share and was issued in a private, unregistered transaction relying on Section 4(a)(2) and Regulation D exemptions.
HealthLynked Corp. reported several leadership changes. The company appointed Duncan McGillivray as Chief Operating Officer effective December 8, 2025. He has more than 30 years of experience in healthcare, capital markets, and large-scale project finance, including work on a targeted $40M construction project in Miami and helping close over $200 million of funded projects for community health facilities.
His initial base salary is $120,000 per year, increasing to $150,000 if the company successfully uplists to the Nasdaq Capital Market, and he will receive up to 180,000 restricted stock units, split between time-based and uplisting-based vesting. Effective December 1, 2025, HealthLynked also expanded its Board from six to eight members and appointed Jason Bishara and Chris G. Pulos as non‑employee directors, each receiving annual compensation of $20,000 in common stock vesting quarterly over one year.